A double‐blind study on ulotaront's impact on weight‐related parameters in schizophrenia patients with metabolic syndrome and prediabetes: Part <scp>II</scp>
Despite the sample size constraints due to early study termination, all key endpoint trends and statistically significant differences favoured ulotaront over previous antipsychotics, lending support that ulotaront may improve antipsychotic-induced weight-associated markers. Liver fibro-inflammation may serve as a potential marker for antipsychotic-induced MetSyn and prediabetes, and possible treatment target. Further research is needed to build on these findings.
Authors
- Snezana Milanovic (ORCID: https://orcid.org/0009-0000-7586-1583)
- Yu‐Luan Chen (ORCID: https://orcid.org/0000-0002-2866-3602)
- Robert Lew
- Kuangnan Xiong (ORCID: https://orcid.org/0009-0006-4898-539X)
- C. van Dehn
- Yongquan Lai
- Seth C. Hopkins (ORCID: https://orcid.org/0000-0003-3999-2281)
- Gerald R. Galluppi (ORCID: https://orcid.org/0000-0001-6705-3084)
- Kenneth S. Koblan (ORCID: https://orcid.org/0000-0001-6103-2629)
- Manu V. Chakravarthy (ORCID: https://orcid.org/0000-0002-3699-150X)
- Edward Jackson (ORCID: https://orcid.org/0000-0002-6976-7619)
- Emily Casavant
Institutions
- Edison Pharmaceuticals (United States) (US)
- Sumitomo Dainippon Pharma (United States) (US)
- Carmot Therapeutics (United States) (US)
- Numerical Algorithms Group (United Kingdom) (GB)
- University of Jamestown (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-10-22
- DOI
- https://doi.org/10.1111/dom.70110
- Primary Topic
- Schizophrenia research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Otsuka Pharmaceutical